Skip to main content

Table 3 prognostic factors of progression free survival

From: Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas

 Bivariate analysesMultivariate analysis
HR and 95% CIp-valueHR and 95% CIp-value
Female (vs. Male)1.42 [0,70; 2.87]0.332  
Age1.01 [0.98; 1.03]0.574  
Pre- cancerous lesion
 nevus vs. de novo0.18 [0.02; 1.47]0.109  
 PAM vs. de novo1.40[0.57;3.42]0.465  
Clinical stage
 T2 vs. T13.01 [1.04; 8.73]0.0423.19 [1.04; 9.80]0.042
 T3 vs. T14.33 [1.88; 9.97]0.0014.75 [1.47; 15.28]0.009
Pathological stage
 pT2 vs. pT13.18 [1.16; 8.67]0.024  
 pT3 vs. pT14.32 [1.82; 10.22]0.001  
 Unifocal0.87 [0.38;2.02]0.751  
Tumor epicenter caruncle and conjunctival folds + lids vs. bulbar2.95[1.24;7.03]0.015  
Quadrangular involvement (degree)
 90 to 180 vs. < 901.26 [0.46; 3.47]0.648  
  > 180 vs. < 902.62 [0.75; 9.47]0.132  
Epithelioid type3.29 [1.44; 7.52]0.0052.68 [1.12; 6.43]0.027
Margins
 R1 vs. R00.87 [0.42; 1.80]0.704  
 R2 vs. R00.89 [0.11; 7.03]0.909  
Number of mitoses> = 21.09 [0.54; 2.18]0.808  
Ulceration3.10 [1.26; 7.62]0.014  
Thickness > = 2 mm1.06 [0.46; 2.46]0.892  
Diameter > = 7 mm1.14 [0.57; 2.29]0.705  
Treatment
 Mitomycin1.10 [0.35; 3.47]0.875  
 Cryotherapy0.88 [0.37; 2.11]0.775  
  1. aHR for nevus not computed since no events in this stratum
  2. Abbreviations: T: tumor, R0: complete resection, R1: microscopic resection, R2: macroscopic resection, HR: hazard ratio; CI: Confidence interval; vs.: versus, primary acquired melanosis (PAM)